News

BMJ1d
Prognostic laboratory markers of joint damage in rheumatoid arthritis
Objective: To investigate whether determination of a set of laboratory markers at baseline provides prognostic information on joint damage in hands and feet in rheumatoid arthritis. Methods: 183 ...
BMJ1d
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
Background An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ...
BMJ1d
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of ...
BMJ1d
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis
Objectives Clinical heterogeneity is a cardinal feature of systemic sclerosis (SSc). Hallmark SSc autoantibodies are central to diagnosis and associate with distinct patterns of skin-based and ...
BMJ2d
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
2 Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands 3 Rheumatology Department, Maastricht University Medical Center, Maastricht, The Netherlands Background The ...
BMJ3d
Increased mortality in ankylosing spondylitis is related to disease activity
1 Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway 2 Department of Rheumatology, Rikshospitalet-Radiumhospitalet University Hospital, Oslo, Norway Correspondence to ...
BMJ3d
Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis
Objective To identify predictors of poorer physical function in established psoriatic arthritis (PsA). Methods PsA patients with disease duration of ≥10 years were identified from the Bath ...
BMJ3d
Six months open label trial of leflunomide in active ankylosing spondylitis
Objective: To examine the potential therapeutic effects of leflunomide in patients with active AS in an open label study. Patients and methods: Twenty patients with AS fulfilling the 1984 modified New ...
BMJ3d
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Objective: To examine the therapeutic effect of the interleukin 1 (IL1) receptor antagonist anakinra in ankylosing spondylitis in an open label trial. Methods: Anakinra (100 mg) was given ...
BMJ3d
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Correspondence to Dr Adi Diab, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center FC3004, 1515 Holcombe Blvd Houston, Texas; adiab{at}mdanderson.org Background Immune ...
BMJ3d
High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis
Objective Dactylitis is a hallmark of psoriatic arthritis (PsA) where flexor tenosynovitis is common. This study explored the microanatomical basis of dactylitis using high-resolution MRI (hrMRI) to ...
BMJ4d
Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis
1 UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland 2 UCD School of Mathematical Sciences, University College Dublin, Dublin, Ireland Objective ...